K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 57.95 HKD 0.43% Market Closed
Market Cap: 17.3B HKD

Income Statement

Earnings Waterfall
KeyMed Biosciences Inc

Revenue
872.2m CNY
Cost of Revenue
-41.9m CNY
Gross Profit
830.3m CNY
Operating Expenses
-1.1B CNY
Operating Income
-289.3m CNY
Other Expenses
31.9m CNY
Net Income
-257.3m CNY

Income Statement
KeyMed Biosciences Inc

Rotate your device to view
Income Statement
Currency: CNY
Dec-2021 Jun-2022 Dec-2022 Jun-2023 Dec-2023 Jun-2024 Dec-2024 Jun-2025
Revenue
Interest Expense
11
6
8
16
17
17
18
17
Revenue
110
N/A
210
+91%
100
-52%
327
+227%
354
+8%
82
-77%
428
+424%
872
+104%
Gross Profit
Cost of Revenue
(17)
(20)
(3)
(15)
(37)
(26)
(12)
(42)
Gross Profit
93
N/A
191
+105%
97
-49%
312
+220%
317
+2%
56
-82%
416
+642%
830
+100%
Operating Income
Operating Expenses
(3 910)
(558)
(576)
(700)
(751)
(846)
(1 007)
(1 120)
Selling, General & Administrative
(92)
(117)
(134)
(165)
(177)
(208)
(299)
(412)
Research & Development
(358)
(331)
(507)
(593)
(596)
(678)
(735)
(764)
Other Operating Expenses
(3 459)
(110)
65
58
22
39
27
57
Operating Income
(3 817)
N/A
(367)
+90%
(479)
-30%
(388)
+19%
(434)
-12%
(790)
-82%
(591)
+25%
(289)
+51%
Pre-Tax Income
Interest Income Expense
(60)
96
175
130
77
55
83
35
Non-Reccuring Items
(16)
11
0
0
0
0
0
0
Total Other Income
0
0
(0)
0
0
0
0
0
Pre-Tax Income
(3 893)
N/A
(260)
+93%
(304)
-17%
(258)
+15%
(356)
-38%
(735)
-106%
(509)
+31%
(254)
+50%
Net Income
Tax Provision
0
0
0
0
(2)
(8)
(6)
(3)
Income from Continuing Operations
(3 893)
(260)
(304)
(258)
(358)
(743)
(515)
(257)
Income to Minority Interest
5
6
(5)
(9)
(2)
(1)
(0)
(0)
Net Income (Common)
(3 887)
N/A
(253)
+93%
(308)
-22%
(267)
+13%
(359)
-35%
(743)
-107%
(515)
+31%
(257)
+50%
EPS (Diluted)
-24.17
N/A
-0.94
+96%
-1.18
-26%
-1
+15%
-1.37
-37%
-2.84
-107%
-1.97
+31%
-0.98
+50%